RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks. » Read More
Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.
Plus, Cramer make the call on IBM, CSX, Celgene and more.
This is how you balance Mad Money stock picks with your own portfolio.
This biotech sells its treatment to a niche clientele for big money.
Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.
It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
Options activity is picking up in Johnson & Johnson stock. Why?
Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.
Following are the day’s biggest winners and losers. Find out why shares of Fortune Brands and Northwest Airlines popped while Thornburg Mortgage and Cal-Maine Foods dropped.
The Dow, S&P and Nasdaq are just points away from breaking their monthly losing streaks at 4 straight months of losses. Here's what they would need to rally today to have their first positive month since October:
Vertex Pharmaceuticals said Merck & Co halted enrollment on trials of their investigational leukemia drug MK-0457 due to a potential heart safety issue in one patient.
There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.
For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.
Quarterly earnings reports and new drug trial data were some of the catalysts behind the most actively traded stocks on Wednesday.
More than 4.1 million Americans live with hepatitis C, a viral infection of the liver. That's why Jason Kolbert, a biotechnology analyst at Susquehanna Financial Group, advised "Squawk Box" viewers to stock up on therapy stocks.
PDL BioPharma, United Online, Vertex Pharma: In under a minute, Cramer's got calls on all three.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
New York Stock Exchange, Airgas, CMGI and many more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks posted modest gains across the board--with financial, technology and energy stocks showing strength.